speb/financial-data huggingface dataset:
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Operating Revenue: 2687160000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 585600000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 66398630.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 66398630.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 40190000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 40190000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 12530000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 12530000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 2266700000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 2266700000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 759240000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 759240000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: -263740000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 44230000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 44230000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 81900000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 27700000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 502740000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 115580000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Other Payable: 101990000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Other Properties: 88370000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 88370000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 1175170000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 1175170000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Payables: 97340000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Payables: 201200000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 10140000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 40860000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 40860000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Pretax Income: 698590000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 87080000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: -2970000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Purchase Of Business: -936570000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -2556340000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -3480000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 964380000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 217200000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 81310000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 23050000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 4260000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 2609340000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 357180000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 211040000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Share Issued: 66398630.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 66398630.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Special Income Charges: 196871000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: -2120000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Stock Based Compensation: 68040000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 2399500000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 2399500000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 1543330000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 1543330000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 40857094.40
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: -517096.35
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Tax Provision: 144980000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 21250000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.21
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.24
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -81430000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Total Assets: 2782600000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 2782600000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 2399500000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 2399500000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Total Debt: 92390000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 92390000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 2399500000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 2399500000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Total Expenses: 2257760000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 521510000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 383100000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 383100000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 1170660000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 1170660000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 124060000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 124060000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 196871000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: -2119000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 196871000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -2120000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Working Capital: 1352900000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 1352900000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 368250000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 756120000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 67468750.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 1.60
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 269270000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 23530000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 23530000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 68322785.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 1.58
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 107950000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — EBIT: 146850000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — EBITDA: 170380000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 486850000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 2540000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 2540000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income: 107950000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 107950000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 107950000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 107950000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 107950000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 107950000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -2540000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -2540000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 170380000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 107950000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Operating Income: 118600000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 756120000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 28250000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 150310000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 144310000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 269270000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 23530000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 36360000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.25
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 637520000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
JAGSNPHARM.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 331890000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 744650000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 129700000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 225660000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 17490000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 66882979.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 1.88
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 88360000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 133270000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 127930000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 1593080000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 133270000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 2528400000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 272280000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 2017920000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 16470000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 16470000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 332680000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 11430000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 23860000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 23860000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 67240642.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 1.87
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 125740000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — EBIT: 170750000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — EBITDA: 194610000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Goodwill: 96930000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 817760000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 81860000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 472370000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 2650000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 2650000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 158470000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 2528400000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 17490000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 71890000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 71890000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 10230000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income: 125740000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 125740000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 125740000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 125740000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 125740000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 125740000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -2650000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -2650000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 81860000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 1710640000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 40420000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 194610000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Normalized Income: 125740000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Operating Income: 140480000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 744650000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 66631254.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 40710000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 38630000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 2395130000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 720830000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 47270000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 30270000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 126280000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 81860000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 1465150000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Payables: 145390000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Pretax Income: 168100000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 272280000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 23860000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Restructuring And Mergern Acquisition: 0.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 66631254.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Special Income Charges: 0.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 2528400000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 1710640000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 42360000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.25
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 2990280000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 2528400000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 88360000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 2528400000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 604170000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 461880000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 972360000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 129200000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 15690000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items: 0.00
JAGSNPHARM.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 0.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 1685240000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 326100000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 729450000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 65574850.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 1.67
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 264530000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 23860000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 23860000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 66369697.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 1.65
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 109510000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — EBIT: 147780000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — EBITDA: 171640000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 464920000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 2570000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 2570000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income: 109510000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 109510000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 109510000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 109510000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 109510000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 109510000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -2570000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -2570000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 192430000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 125188761.10
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Operating Income: 138820000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 729450000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 29750000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 126450000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Other Special Charges: 20790000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 145210000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 264530000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 23860000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -20790000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -5111238.90
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 35700000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.25
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 590630000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -20790000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -20790000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — +Operating Expense: 1342200000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 315960000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — +Total Revenue: 2872250000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 642030000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 115810000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 115810000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 171910000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 171910000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 851110000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 851110000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 67315625.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 70096800.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Basic EPS: 6.40
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 1.25
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 110280000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -1480000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 81650000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 81650000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 133930000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 133930000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 100420000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 100420000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 1061850000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 1061850000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -166580000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Change In Inventory: 5280000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: -8760000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: 1720000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Change In Payable: 18470000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -40150000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -23940000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Changes In Cash: -9860000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Common Stock: 133930000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 133930000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 2761720000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 2761720000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Common Stock Issuance: 66290000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 1043750000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 237670000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Current Assets: 1430890000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 1430890000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 15760000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 15760000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 15760000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 15760000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 282980000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 282980000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 13240000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 13240000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Depreciation: 94440000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 94440000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 94440000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 23190000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 94440000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 23190000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 68275753.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 72414050.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Diluted EPS: 6.31
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 1.21
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 430820000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 87621000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — EBIT: 585460000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — EBIT: 120080000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — EBITDA: 679900000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — EBITDA: 143270000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — End Cash Position: 100420000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -121490000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 466640000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Goodwill: 96930000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Goodwill: 96930000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 779600000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 779600000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 73500000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 73500000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Gross Profit: 1828500000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 404360000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Interest Expense: 10280000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 2520000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 10280000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 2520000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -8990000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 101370000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Inventory: 146430000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 146430000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 2761720000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 2761720000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -356490000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 851110000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 851110000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Issuance Of Capital Stock: 66290000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 65890000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 65890000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 65890000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 65890000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 11770000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 11770000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Net Business Purchase And Sale: -12000000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: 66290000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Net Income: 430820000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income: 87621000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 430820000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 87621000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 430820000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 87621000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 430820000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 87621000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 430820000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 87621000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 575180000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 430820000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 87621000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Net Interest Income: -10280000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -2520000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: -444380000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -10280000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -2520000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Net PPE: 73500000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 73500000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -1480000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 1982120000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 1982120000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 44410000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 44410000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 700690000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 143270000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Normalized Income: 446392077.96
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 87621000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 468120000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Operating Income: 486300000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Operating Income: 88400000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Operating Revenue: 2872250000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 642030000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 66962250.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 66962250.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 50700000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 50700000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 25240000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 25240000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 2627790000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 2627790000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 682670000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 682670000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: -86360000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 31010000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 31010000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 119950000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 31680000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 540360000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 137320000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Other Properties: 73500000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 73500000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 961430000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 961430000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Payables: 121380000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Payables: 121380000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Pretax Income: 575180000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 117560000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: -560000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Purchase Of Business: -12000000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -1984020000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -1480000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 1043750000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 237670000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 94440000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 23190000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 1539640000.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Share Issued: 66962250.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 66962250.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Special Income Charges: -20790000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: 0.00
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Stock Based Compensation: 28050000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 2761720000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 2761720000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 1982120000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 1982120000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: -5217922.04
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Tax Provision: 144360000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 29940000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.25
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.25
JAGSNPHARM.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -118980000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Total Assets: 3166770000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 3166770000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 2761720000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 2761720000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Total Debt: 81650000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 81650000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 2761720000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 2761720000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Total Expenses: 2385950000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 553630000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 405050000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 405050000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 1735880000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 1735880000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 122070000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 122070000.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 5570000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 5570000.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Total Unusual Items: -20790000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: 0.00
JAGSNPHARM.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: -20790000.00
JAGSNPHARM.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2026-03-31) — Working Capital: 1147910000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 1147910000.00
JAGU balance_sheet (annual, 2022-12-31) — Accounts Payable: 0.00
JAGU balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 1.00
JAGU balance_sheet (annual, 2022-12-31) — Capital Stock: 0.00
JAGU balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 0.00
JAGU balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 0.00
JAGU balance_sheet (annual, 2022-12-31) — Common Stock: 0.00
JAGU balance_sheet (annual, 2022-12-31) — Common Stock Equity: 1.00
JAGU balance_sheet (annual, 2022-12-31) — Current Assets: 1.00
JAGU balance_sheet (annual, 2022-12-31) — Current Liabilities: 0.00
JAGU balance_sheet (annual, 2022-12-31) — Invested Capital: 1.00
JAGU balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 1.00
JAGU balance_sheet (annual, 2022-12-31) — Non Current Prepaid Assets: 0.00
JAGU balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 20193777.00
JAGU balance_sheet (annual, 2022-12-31) — Other Receivables: 1.00
JAGU balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 0.00
JAGU balance_sheet (annual, 2022-12-31) — Prepaid Assets: 0.00
JAGU balance_sheet (annual, 2022-12-31) — Receivables: 1.00
JAGU balance_sheet (annual, 2022-12-31) — Retained Earnings: 0.00
JAGU balance_sheet (annual, 2022-12-31) — Share Issued: 20193777.00
JAGU balance_sheet (annual, 2022-12-31) — Stockholders Equity: 1.00
JAGU balance_sheet (annual, 2022-12-31) — Tangible Book Value: 1.00
JAGU balance_sheet (annual, 2022-12-31) — Total Assets: 1.00
JAGU balance_sheet (annual, 2022-12-31) — Total Capitalization: 1.00
JAGU balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 1.00
JAGU balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 0.00
JAGU balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 0.00
JAGU balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
JAGU balance_sheet (annual, 2022-12-31) — Working Capital: 1.00
JAGU income_statement (annual, 2023-12-31) — +Operating Expense: 97728.00
JAGU income_statement (annual, 2023-12-31) — +Total Revenue: 0.00
JAGU balance_sheet (annual, 2023-12-31) — Accounts Payable: 9831.00
JAGU balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: 0.00
JAGU balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 580100.00
JAGU cash_flow (annual, 2023-12-31) — Asset Impairment Charge: 0.00
JAGU income_statement (annual, 2023-12-31) — Basic Average Shares: 20193777.00
JAGU income_statement (annual, 2023-12-31) — Basic EPS: 0.00
JAGU cash_flow (annual, 2023-12-31) — Beginning Cash Position: 0.00
JAGU cash_flow (annual, 2023-12-31) — Capital Expenditure: -200000.00
JAGU balance_sheet (annual, 2023-12-31) — Capital Stock: 0.00
JAGU balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 394920.00
JAGU balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 394920.00
JAGU cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: 865100.00
JAGU cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: -388381.00
JAGU cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: -81799.00
JAGU cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 9831.00
JAGU cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: 0.00
JAGU cash_flow (annual, 2023-12-31) — Change In Working Capital: 9831.00
JAGU cash_flow (annual, 2023-12-31) — Changes In Cash: 394920.00
JAGU balance_sheet (annual, 2023-12-31) — Common Stock: 0.00
JAGU balance_sheet (annual, 2023-12-31) — Common Stock Equity: 488470.00
JAGU cash_flow (annual, 2023-12-31) — Common Stock Issuance: 550100.00
JAGU balance_sheet (annual, 2023-12-31) — Current Assets: 624920.00
JAGU balance_sheet (annual, 2023-12-31) — Current Liabilities: 324831.00
JAGU cash_flow (annual, 2023-12-31) — Deferred Income Tax: 0.00
JAGU cash_flow (annual, 2023-12-31) — Deferred Tax: 0.00
JAGU cash_flow (annual, 2023-12-31) — Depreciation: 0.00
JAGU cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 0.00
JAGU income_statement (annual, 2023-12-31) — Depreciation Amortization Depletion Income Statement: 0.00
JAGU cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 0.00
JAGU income_statement (annual, 2023-12-31) — Depreciation And Amortization In Income Statement: 0.00
JAGU income_statement (annual, 2023-12-31) — Depreciation Income Statement: 0.00
JAGU income_statement (annual, 2023-12-31) — Diluted Average Shares: 20193777.00
JAGU income_statement (annual, 2023-12-31) — Diluted EPS: 0.00
JAGU income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -91630.00
JAGU income_statement (annual, 2023-12-31) — EBIT: -97728.00
JAGU income_statement (annual, 2023-12-31) — EBITDA: -97728.00
JAGU cash_flow (annual, 2023-12-31) — End Cash Position: 394920.00
JAGU cash_flow (annual, 2023-12-31) — Financing Cash Flow: 865100.00
JAGU cash_flow (annual, 2023-12-31) — Free Cash Flow: -281799.00
JAGU income_statement (annual, 2023-12-31) — Gain On Sale Of Security: 5924.00
JAGU income_statement (annual, 2023-12-31) — General And Administrative Expense: 97728.00
JAGU balance_sheet (annual, 2023-12-31) — Gross PPE: 0.00
JAGU income_statement (annual, 2023-12-31) — Impairment Of Capital Assets: 0.00
JAGU cash_flow (annual, 2023-12-31) — Income Tax Paid Supplemental Data: 0.00
JAGU income_statement (annual, 2023-12-31) — Interest Income: 174.00
JAGU income_statement (annual, 2023-12-31) — Interest Income Non Operating: 174.00
JAGU cash_flow (annual, 2023-12-31) — Interest Paid Supplemental Data: 0.00
JAGU balance_sheet (annual, 2023-12-31) — Invested Capital: 488470.00
JAGU cash_flow (annual, 2023-12-31) — Investing Cash Flow: -388381.00
JAGU cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 550100.00
JAGU balance_sheet (annual, 2023-12-31) — Land And Improvements: 0.00
JAGU cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 550100.00
JAGU income_statement (annual, 2023-12-31) — Net Income: -91630.00
JAGU income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -91630.00
JAGU income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -91630.00
JAGU income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -91630.00
JAGU income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -91630.00
JAGU cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -91630.00
JAGU income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -91630.00
JAGU income_statement (annual, 2023-12-31) — Net Interest Income: 174.00
JAGU income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: 174.00
JAGU cash_flow (annual, 2023-12-31) — Net Other Financing Charges: 315000.00
JAGU cash_flow (annual, 2023-12-31) — Net Other Investing Changes: -188381.00